ZBIO News & Events

Stock futures are higher ahead of the open, suggesting equities may attempt a recovery after last week's selloff. Markets look poised to open the week with a rebound after a volatile stretch driven largely by energy markets and geopolitical developments in the Middle East.Energy prices are still elevated amid the ongoing conflict involving Iran and disruptions around the Strait of Hormuz. Attacks on energy infrastructure and shipping routes have pushed crude above $100 per barrel at times, forcing markets to price in a persistent geopolitical risk premium.Reports suggest diplomatic and logistical efforts are underway to allow more tankers to pass through the Gulf, which has helped cool some of the extreme volatility seen earlier in the month and supported risk appetite in early trading.Even with the modest improvement in sentiment, the broader macro picture remains fragile. Rising oil prices are feeding inflation concerns just as global growth indicators have begun to soften. Policymakers in the United States and Europe are preparing for upcoming meetings while markets debate whether the energy shock will force a more cautious path on rate cuts later this year.Strategists are increasingly warning that the path of oil will likely dictate the trajectory for risk assets in the near term. Some analysts have suggested that a severe and prolonged supply disruption could push equities materially lower if crude continues to climb, highlighting how sensitive the current market environment is to geopolitical headlines and energy prices.In pre-market trading, S&P 500 futures rose 1.01%, Nasdaq futures rose 1.19% and Dow futures rose 0.85%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -National Storageup 29% after entering an agreement under which Public Storagewill acquire the company in an all-stock transaction with an enterprise value of approximately $10.5BNebiusup 11% after announcing Meta Platformshas committed to purchase additional available compute capacity across certain upcoming Nebius clusters up to a total of $15B over a five-year periodSable Offshoreup 9% after resuming the transportation of hydrocarbons produced at the Santa Ynez Unit through the federally regulated and approved to operate Santa Ynez Pipeline System from Las Flores Canyon to Pentland Station at the direction of the United States Secretary of Energy, Chris WrightMicronup 4% after completing the acquisition and assumed ownership of Powerchip Semiconductor Manufacturing Corporation's P5 site in Tongluo, Miaoli County, TaiwanNeoGenomicsup 3% after receiving the PanTracer LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services ProgramUP AFTER EARNINGS -WWup 11%Lifecoreup 3%Dollar Treeup 1%Townsquare Mediaup 1%DOWN AFTER EARNINGS -Zenas BioPharmadown 1%KE Holdingsdown 1%

As of December 31, 2025, the Company's cash, cash equivalents and investments were $360.5 million. The Company expects that its cash, cash equivalents and investments, as of December 31, 2025, together with the net proceeds received to date in the first quarter of 2026 from sales under our ATM program and the proceeds available from the debt arrangement with investment funds managed by Pharmakon will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2027, and assuming receipt of a potential $75.0 million from the investment funds managed by Pharmakon and $75.0 million from Royalty Pharma contingent upon FDA approval of obexelimab for the treatment of IgG4-RD, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2027.

Reports revenue $0 vs. $5M last year. "Following the highly positive Phase 3 INDIGO results reported earlier this year, we enter 2026 with strong momentum as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. We are on track to submit obexelimab marketing applications for the treatment of IgG4-RD to the FDA in the second quarter and to the EMA in the second half of the year, both major milestones for the program and patients living with this disease," said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. "We look forward to progressing multiple Zenas pipeline programs this year, including the orelabrutinib progressive MS Phase 3 studies, clinical development of our oral IL-17 inhibitor, ZB021, and the advancement of an exciting new molecule, ZB014, a half-life extended anti-CD-19 and FcgammaRIIb antibody. In addition, we expect to report topline overall and biomarker population results of the Phase 2 SunStone trial of obexelimab in SLE. Collectively, these programs represent the foundation for compelling franchises across numerous areas of unmet need for patients living with immune mediated diseases. We are also very pleased to announce today a non-dilutive financing arrangement with Pharmakon, a respected leader in strategic life sciences funding. This partnership strengthens our balance sheet and provides us with the financial flexibility to commercialize obexelimab while investing in our broader pipeline."